Calprotectine in Spondyloarthritis

Centre Hospitalier Universitaire de Nice

Status: Enrolling

Conditions: Spondylarthritis

Treatments: Other: NO INTERVENTION

Study type: Observational

Funder types: Other

Identifiers

NCT05555433

22Rhumato01

Details and patient eligibility

About

To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly used in inflammatory diseases of the digestive tract. A growing interest in this biomarker is emerging in rheumatology, several publications have focused on its interest in rheumatoid arthritis, highlighting an association between serum calprotectin levels and disease activity. In spondyloarthritis, a few studies seem to show that it could be a marker of disease activity. Although a 2012 study found no difference in serum calprotectin levels between subjects with spondyloarthritis and controls. Still others have shown that it could be a predictive factor of radiological evolution in the same disease key. These data support, despite the questionable results of the Klingberg study, the value of this dosage in spondyloarthritis. The objective of this work is to show that this assay could be useful to differentiate spondyloarthritis from other pathologies with similar clinical presentation such as fibromyalgia. Difficulties classically encountered in common practice in rheumatology

Enrollment: 190 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients in the active line of the rheumatology department with one of the following criteria:

active spondyloarthritis (BASDAI >4), or spondyloarthritis in low activity (BASDAI<4), or fibromyalgia without associated inflammatory rheumatism, or healthy subjects (without inflammatory rheumatism and without fibromyalgia. Patients who have not objected to the use of their samples

Exclusion criteria

Minor patient Subject not affiliated to the social security system Subject deprived of liberty Patient under guardianship or curatorship

Trial design

190 participants in 4 patient groups

active spondyloarthritis

Description:

subjects with active spondyloarthritis with a BASDAI greater than 4

Treatment:

Other: NO INTERVENTION

remission spondyloarthritis

Description:

subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4

Treatment:

Other: NO INTERVENTION

controls without spondyloarthritis

Description:

controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia

Treatment:

Other: NO INTERVENTION

fibromyalgia

Description:

subjects with fibromyalgia

Treatment:

Other: NO INTERVENTION